{"entity":{"id":"nct07448922","kind":"trial","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","aka":[],"tldr":"A phase 2 trial of Carboplatin and Bevacizumab in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.","summary":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors is a phase 2 interventional study registered as NCT07448922 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 280 participants planned, started 2026-04-08 and due to reach its primary completion in 2027-12-31. Interventions recorded: SKB518 for injection, Carboplatin (AUC 5) and Bevacizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07448922","url":"https://clinicaltrials.gov/study/NCT07448922"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","bevacizumab"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07448922","phase":"2","setting":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignancies","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","participation":[{"nct":"NCT07448922","source":"https://clinicaltrials.gov/study/NCT07448922","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"385c5be0f56bb0166d68718baeed2533db9ee90d2ea1d7d5b0a3ebd79d0724ff","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-12","leadSponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":280,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["China"]}],"started":"2026-04-08","startedType":"actual","enrolled":280,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07448922/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}